• Anthony P Gulati, Benjamin Krantz, Rebecca A Moss, Wendy N Moyal, Dawn A Tsushima, Kelley B Mowatt, Stephen Schreibman, and Robert L Fine.
• Experimental Therapeutics Program, Division of Medical Oncology, New York Presbyterian-Columbia University Medical Center, New York, N.Y., USA.
• Oncology. 2013 Jan 1; 84 (3): 127-34.

BackgroundNeuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidity of MEN-1 and MEN-2 is often due to the symptomatology of the endocrine hormones produced, and the mortality mainly occurs from hepatic dysfunction incurred by liver metastases. At present, there is essentially no effective cure once the tumor has metastasized to the liver.PatientWe present a patient with progressive, metastatic MEN-1 with the classic '3 P's' triad of neuroendocrine tumor of the pancreas, parathyroid adenoma and a pituitary adenoma.ResultsAfter progression on high-dose Sandostatin LAR (60 mg/month) and multiple surgeries, the patient had a partial response (40% decrease) to a novel regimen of capecitabine and temozolomide (CAPTEM) and progression-free survival of 18 months. He had minor grade 1 toxicities and no grade 2, 3 or 4 toxicities.DiscussionThe history and treatment options for MEN-1/2 cancers are reviewed, as well as the data behind our novel regimen, CAPTEM.ConclusionThe CAPTEM regimen is a tolerable, safe, easy to administer oral regimen with possible efficacy for MEN-1 tumors.Copyright © 2012 S. Karger AG, Basel.

22 keywords...

hide…